FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210588772> ?p ?o ?g. }

• W4210588772 abstract "From this retrospective study, we aimed to (1) describe the prevalence and characteristics of non-criteria features in primary antiphospholipid syndrome (p-APS) and (2) determine their prognostic value.This retrospective French multicenter cohort study included all patients diagnosed with p-APS (Sydney criteria) between January 2012 and January 2019. We used Kaplan-Meier and adjusted Cox proportional hazards models to compare the incidence of relapse in p-APS with and without non-criteria manifestations.One hundred and seventy-nine patients with p-APS were included during the study time, with a median age of 52.50 years [39.0; 65.25] and mainly women (n = 112; 62.6%). Among them, forty-three patients (24.0%) presented at least one non-criteria manifestation during the follow-up: autoimmune cytopenias (n = 17; 39.5%), Libman Sachs endocarditis (n = 5; 11.6%), APS nephropathy (n = 4; 9.3%), livedo reticularis (n = 8; 18.6%), and neurological manifestations (n = 12; 27.9%). In comparison to p-APS without any non-criteria manifestations (n = 136), p-APS with non-criteria features had more arterial thrombosis (n = 24; 55.8% vs n = 48; 35.3%; p = 0.027) and more frequent pre-eclampsia (n = 6; 14.3% vs n = 4; 3.1%; p = 0.02). The prevalence of triple positivity was significantly increased in patients with non-criteria features (n = 20; 47.6% vs n = 25; 19.8%; p = 0.001). Patients with p-APS and non-criteria manifestations (n = 43) received significantly more additional therapies combined with vitamin K antagonists and/or antiaggregants. Catastrophic APS (CAPS) tended to be more frequent in p-APS with non-criteria features (n = 2; 5.1% vs none; p = 0.074). The p-APS with non-criteria manifestations had significantly increased rates of relapse (n = 20; 58.8% vs 33; 33.7%; p = 0.018) in bivariate analysis, but in survival analyses, the hazard ratio (HR) of relapse was not significantly different between the two groups (HR at 1.34 [0.67; 2.68]; p = 0.40).The presence of non-criteria features is important to consider, as they are associated with particular clinical and laboratory profiles, increased risk of relapse, and need for additional therapies. Prospective studies are necessary to better stratify the prognosis and the management of p-APS." @default.
• W4210588772 created "2022-02-08" @default.
• W4210588772 creator A5002179108 @default.
• W4210588772 creator A5003714626 @default.
• W4210588772 creator A5009018227 @default.
• W4210588772 creator A5009414756 @default.
• W4210588772 creator A5012333119 @default.
• W4210588772 creator A5016101708 @default.
• W4210588772 creator A5018066435 @default.
• W4210588772 creator A5034206318 @default.
• W4210588772 creator A5035754619 @default.
• W4210588772 creator A5036173072 @default.
• W4210588772 creator A5038884673 @default.
• W4210588772 creator A5041077575 @default.
• W4210588772 creator A5045698950 @default.
• W4210588772 creator A5065425860 @default.
• W4210588772 creator A5071681341 @default.
• W4210588772 creator A5074489186 @default.
• W4210588772 creator A5076290258 @default.
• W4210588772 creator A5084806299 @default.
• W4210588772 creator A5087386909 @default.
• W4210588772 date "2022-01-25" @default.
• W4210588772 modified "2023-10-10" @default.
• W4210588772 title "Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study" @default.
• W4210588772 cites W1963494811 @default.
• W4210588772 cites W1967516704 @default.
• W4210588772 cites W2050117403 @default.
• W4210588772 cites W2054330426 @default.
• W4210588772 cites W2066719903 @default.
• W4210588772 cites W2119266650 @default.
• W4210588772 cites W2120492526 @default.
• W4210588772 cites W2489967110 @default.
• W4210588772 cites W2584721196 @default.
• W4210588772 cites W2611488218 @default.
• W4210588772 cites W2623359522 @default.
• W4210588772 cites W2741174708 @default.
• W4210588772 cites W2781935993 @default.
• W4210588772 cites W2799726057 @default.
• W4210588772 cites W2890833593 @default.
• W4210588772 cites W2966721681 @default.
• W4210588772 cites W3094240398 @default.
• W4210588772 doi "https://doi.org/10.1186/s13075-022-02726-9" @default.
• W4210588772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35078523" @default.
• W4210588772 hasPublicationYear "2022" @default.
• W4210588772 type Work @default.
• W4210588772 citedByCount "8" @default.
• W4210588772 countsByYear W42105887722022 @default.
• W4210588772 countsByYear W42105887722023 @default.
• W4210588772 crossrefType "journal-article" @default.
• W4210588772 hasAuthorship W4210588772A5002179108 @default.
• W4210588772 hasAuthorship W4210588772A5003714626 @default.
• W4210588772 hasAuthorship W4210588772A5009018227 @default.
• W4210588772 hasAuthorship W4210588772A5009414756 @default.
• W4210588772 hasAuthorship W4210588772A5012333119 @default.
• W4210588772 hasAuthorship W4210588772A5016101708 @default.
• W4210588772 hasAuthorship W4210588772A5018066435 @default.
• W4210588772 hasAuthorship W4210588772A5034206318 @default.
• W4210588772 hasAuthorship W4210588772A5035754619 @default.
• W4210588772 hasAuthorship W4210588772A5036173072 @default.
• W4210588772 hasAuthorship W4210588772A5038884673 @default.
• W4210588772 hasAuthorship W4210588772A5041077575 @default.
• W4210588772 hasAuthorship W4210588772A5045698950 @default.
• W4210588772 hasAuthorship W4210588772A5065425860 @default.
• W4210588772 hasAuthorship W4210588772A5071681341 @default.
• W4210588772 hasAuthorship W4210588772A5074489186 @default.
• W4210588772 hasAuthorship W4210588772A5076290258 @default.
• W4210588772 hasAuthorship W4210588772A5084806299 @default.
• W4210588772 hasAuthorship W4210588772A5087386909 @default.
• W4210588772 hasBestOaLocation W42105887721 @default.
• W4210588772 hasConcept C120665830 @default.
• W4210588772 hasConcept C121332964 @default.
• W4210588772 hasConcept C126322002 @default.
• W4210588772 hasConcept C141071460 @default.
• W4210588772 hasConcept C167135981 @default.
• W4210588772 hasConcept C198451711 @default.
• W4210588772 hasConcept C2776874634 @default.
• W4210588772 hasConcept C2779134260 @default.
• W4210588772 hasConcept C2779974317 @default.
• W4210588772 hasConcept C2780868729 @default.
• W4210588772 hasConcept C50382708 @default.
• W4210588772 hasConcept C61511704 @default.
• W4210588772 hasConcept C71924100 @default.
• W4210588772 hasConcept C72563966 @default.
• W4210588772 hasConcept C90924648 @default.
• W4210588772 hasConceptScore W4210588772C120665830 @default.
• W4210588772 hasConceptScore W4210588772C121332964 @default.
• W4210588772 hasConceptScore W4210588772C126322002 @default.
• W4210588772 hasConceptScore W4210588772C141071460 @default.
• W4210588772 hasConceptScore W4210588772C167135981 @default.
• W4210588772 hasConceptScore W4210588772C198451711 @default.
• W4210588772 hasConceptScore W4210588772C2776874634 @default.
• W4210588772 hasConceptScore W4210588772C2779134260 @default.
• W4210588772 hasConceptScore W4210588772C2779974317 @default.
• W4210588772 hasConceptScore W4210588772C2780868729 @default.
• W4210588772 hasConceptScore W4210588772C50382708 @default.
• W4210588772 hasConceptScore W4210588772C61511704 @default.
• W4210588772 hasConceptScore W4210588772C71924100 @default.
• W4210588772 hasConceptScore W4210588772C72563966 @default.
• W4210588772 hasConceptScore W4210588772C90924648 @default.
• W4210588772 hasIssue "1" @default.

• next